Biological and Pharmaceutical Bulletin
The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 15,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English.
The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Sumio Ohtsuki
Faculty of Life Sciences, Kumamoto University
Read more
10,863 registered articles
(updated on July 02, 2022)
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
2.264
2021 Journal Impact Factor (JIF)
JOURNAL PEER REVIEWED FREE ACCESS FULL-TEXT HTML ADVANCE PUBLICATION
Scopus Pubmed
Featured article
Volume 45 (2022) Issue 7 Pages 806-812
Health Effects and Safety Assurance of Nanoparticles in Vulnerable Generations Read more
Editor's pick

Despite the usefulness of nanoparticles, there are now safety concerns about their use. Therefore, the importance of evaluating the safety of vulnerable generations such as pregnant women and infants, who are highly sensitive to chemical substances, has been pointed out worldwide. From this perspective, to analyze the risk from nanoparticles to vulnerable generations, nano-safety science and nano-safety design research has been conducted. The findings of these studies will lead not only to develop a nanotechnology that will enable the sustainable use of nanoparticles; they will also contribute to future developments in the field of health science.

Volume 45 (2022) Issue 7 Pages 813
Foreword Read more
Editor's pick

Recently, therapeutic drug monitoring is recommended for many drugs even though the procedure is not covered by health insurance. This Current Topic focuses on four areas: (1) anticancer drugs, (2) anti-infective agents, (3) antipsychotics/antidepressants, and (4) antibody drugs. Among the drugs that are not approved for insurance coverage in Japan, the drugs for which TDM is recommended and drugs that are likely to be approved in the future are summarized in a review, which include their pharmacokinetic characteristics and the usefulness of TDM.

Volume 45 (2022) Issue 7 Pages 851-855
More than 370-Fold Increase in Antibody Affinity to Estradiol-17β by Exploring Substitutions in the VH-CDR3 Read more
Editor's pick

Antibodies that specifically target biomarkers are essential in clinical diagnosis. Genetic engineering has assisted in designing novel antibodies that offer greater antigen-binding affinities, thus providing more sensitive immunoassays. Authors have succeeded in generating a single-chain Fv fragment (scFv) targeted estradiol-17b (E2) with more than 370-fold improved affinity (Ka 3.2 ´ 1010 M-1), based on a strategy focusing the complementarity-determining region 3 in the VH domain (VH-CDR3). This improvement is the greatest reported for mutagenesis targeting anti-steroid antibodies. The scFv mutant enabled an enzyme-linked immunosorbent assay that provided sensitive dose-response curves for determining E2, the midpoint of which was 4.46 pg/assay.

Volume 45 (2022) Issue 7 Pages 881-887
Hospital-Wide Surveillance of Fracture Risk Assessment by Both FRAX and Medication Patterns in Acute Care Hospital Read more
Editor's pick

Fracture Risk Assessment Tool (FRAX) is a well-known scoring system for predicting the probability of fragility fractures (FF). However, among the factors used in FRAX, glucocorticoid is the only medication factor. Authors assessed the risk of FF at each clinical department using FRAX and medication patterns. As a result, the departments included in the high-risk group by FRAX were not necessarily the same as the departments included in the top group, based on the administered medications. Authors recommend the use of FRAX together with prescribed medications on hospital-wide surveillance of fracture risk assessment.

Volume 45 (2022) Issue 7 Pages 895-903
Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan Read more
Editor's pick

For the patient, the national health insurance of Japan is a wonderful system which can be proud to the world. Efficiency of medical care is an important issue to make this system sustainable into the future. Nivolumab, a breakthrough cancer drug, is widely effective, but its high price raises efficiency concerns. Authors performed model-based cost-effectiveness analyses in first-line and late-line treatment for advanced gastric cancer. The first-line treatment had an incremental cost-effectiveness ratio of more than 7 times that of the late-line treatment. Authors showed challenges between economics and best practices in healthcare.

View all featured articles
Most viewed articles (June 2022)
Share this page
Browse by volume and issue
Announcements from publisher
  • Biol. Pharm. Bull. Vol. 45 No. 7
    Present and Future of Therapeutic Drug Monitoring in New Fields
  • Biol. Pharm. Bull. Vol. 45 No. 6
    Current Topics: Recent Advances of GPCR Studies: An Old-Fashioned Perspective?
  • Announcement of Academic Journals’ Awards
    Biological and Pharmaceutical Bulletin (BPB)
    https://bpb.pharm.or.jp/award/award.pdf

  • Biol. Pharm. Bull. Vol. 44 No. 11
    Current Topics: Recent Advances in the Understanding of Nuclear Receptors- and Drug-Metabolizing Enzymes-Mediated Inter-Individual Differences
  • Biol. Pharm. Bull. Vol. 44 No. 10
    Current Topics: Recent Advances in Research on Vascular Permeability to Establish Novel Therapeutic and Drug Delivery Strategies for Intractable Diseases
feedback
Top